- For the control of serum phosphorus in patients with chronic kidney disease (CKD) who are on dialysis:
- PO 800mg TDS if PO4 5.6-7.4mg/dL
- PO 1200-1600mg TDS if PO4 7.5-8.9mg/dL
- PO 1600mg TDS if PO4 >9mg/dL
- Max: 13g/day
- May titrate by 400-800mg/dose every 2 weeks to maintain PO4 3.5-5.5mg/dL
- Tablet:
- 400mg
- 800mg
- To be taken with meals
Polymeric phosphate binder
It decreases serum phosphate concentrations without changing calcium, aluminum or bicarbonate concentrations
- Vomiting
- Nausea
- Diarrhea
- Dyspepsia
- Abdominal pain
- Flatulence
- Constipation
- Hypersensitivity to components/class
- Hypophosphatemia
- GI obstruction
- IV potassium phosphates
- IV sodium phosphates
Drug Status
| Availability | Prescription only |
| Pregnancy | Consider fat soluble vitamin & folic acid supplementation |
| Breastfeeding | Consider fat soluble vitamin & folic acid supplementation |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Foseal | 800mg | Tablet | 60’s | Emcure Pharma | Lazor Pharma |
| Sevlaren | 400mg | Tablet | 10’s | La Renon | Wessex Pharma |
| Sevlaren | 800mg | Tablet | 10’s | La Renon | Wessex Pharma |